China SXT Pharmaceuticals (NASDAQ:SXTC) Raised to “Hold” at Wall Street Zen

China SXT Pharmaceuticals (NASDAQ:SXTC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Price Performance

SXTC opened at $3.25 on Friday. The company has a 50 day moving average of $175.63 and a 200 day moving average of $16,540.14. China SXT Pharmaceuticals has a 12 month low of $3.07 and a 12 month high of $8,375,880.00. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance.

Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.